Reality Check on Juvenile Idiopathic Arthritis
Market access for juvenile idiopathic arthritis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 70% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In November 2018, the FDA approved Genentech's ACTPen 162 mg/0.9 mL, a single-does prefilled autoinjector, for Actemra (tocilizumab) for administration by caregivers for children at least two years old with active polyarticular juvenile idiopathic arthritis or active systemic juvenile idiopathic arthritis, among other indications
- Key Findings: There are multiple biosimilars in this class that have been approved by the FDA but will not launch until sometime between 2021 and 2023
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.